Combined Triple Therapy in Diabetic Retinopathy (DRP)
- Sponsor
- Johann Wolfgang Goethe University Hospital
- Study ID
- NCT00806169
- Phase
- PHASE3
- Status
- Completed
Conditions
- Diabetic Retinopathy
- Macular Edema
Eligibility Criteria
- Sex
- ALL
- Age
- 21 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
Study Details
The aim of this pilot study was to investigate the effects of an intravitreal combination therapy using triamcinolone and bevacizumab in patients with macular edema due to diabetic retinopathy.
Key Dates
- First listed
- Dec 10, 2008
- Start date
- Apr 30, 2006
- Status verified
- Sep 2012
- Primary completion
- Oct 31, 2008
- Completion
- Nov 30, 2008
Study Design
- Enrollment
- 40 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: 1group I (n=17) nonproliferative DR and ischemic maculopathy
- Experimental: 2group II (n=38) nonproliferative DR without ischemic maculopathy
- Experimental: 3group III (n=18) proliferative DR with or without ischemic maculopathy
Primary Outcome Measure
Best Corrected Visual Acuity [ Time Frame: Day of exam ]
Related Studies
- National Eye Institute Biorepository for Retinal DiseasesRecruiting · National Eye Institute (NEI) · Bethesda, Maryland
- Clinical Applications of Advanced Ophthalmic ImagingRecruiting · University of Miami · Miami, Florida
- Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)Recruiting · University of Alabama at Birmingham · Birmingham, Alabama
- Human iPSC for Repair of Vasodegenerative Vessels in Diabetic RetinopathyRecruiting · University of Alabama at Birmingham · Birmingham, Alabama